Medistim (MEDI)

[TekBot]

First half and second quarter results and financials for 2026 for Medistim ASA

Another strong quarter for sales revenues with 19.5 % growth, ending at MNOK 202.0 (MNOK 169.1). Record sales revenue for the first half with 15.1 % growth, ending at MNOK 403.7 (MNOK 350.6).

Currency neutral sales of own products were up 33.6 % for the quarter and 31.8 % for the first half.
…

Vis børsmeldingen

Strong currency neutral growth in all regions for the quarter; AMERICAS up 46.3 %, APAC up 22.4 % and EMEA up 19.4%.

Third-party distributor sales in Scandinavia decreased 7 % in the quarter and 19.9 % in the first half.

Operating profit (EBIT) grew by 20.6 % for the quarter and ended at MNOK 65.3, resulting in 32.3 % EBIT margin MNOK 54.1, 32.0 % margin). First half operating profit grew 8.0 % ending at a record MNOK 122.4, and 30.3 % EBIT margin (MNOK 113.3, 32.3 % margin).

The share of recurring sales remained high and ended at 67.0 % for the first half (66.8 % for the same period last year).

Medistim announced the establishment of a direct sales operation in Japan, effective from March 16, 2026.

Solid cash position at quarter end with MNOK 100.2 after paying a dividend of NOK 8.00 per share (NOK 6.0), total MNOK 146.3 in May (MNOK 109.4). No interest-bearing bank loans.

The Board will propose that the General Meeting authorize the distribution of quarterly dividends.

Kilde

[Savepig]

Nice

[TekBot]

Flagging – Medistim ASA

I forbindelse med likvidasjon av ACAPITAL Medi Holdco AS (under avvikling) er samtlige av selskapets 1 815 978 aksjer i Medistim ASA blitt delt ut som likvidasjonsutbytte den 31. august 2026. ACAPITAL Medi Holdco AS (under avvikling) eier etter dette ingen aksjer i Medistim ASA. Ved utdelingen av likvidasjonsutbyttet har WQZ Investments Group Ltd mottatt 1 815 978 aksjer i Medistim ASA og eier etter dette 1 815 978 aksjer i Medistim ASA, tilsvarende 9,9% av aksjene og stemmene i selskapet.
…

Vis børsmeldingen

Kilde

[TekBot]

Notification of transactions by persons discharging managerial responsibilities (PDMR) and persons closely associated with them (KRT-1500)

1st of September ACAPITAL Medi Holdco AS and WQZ Investments Group Ltd disclosed the following:

“In connection with the liquidation of ACAPITAL Medi Holdco AS (under liquidation), all of the company’s 1,815,978 shares in Medistim ASA were distributed as liquidation proceeds on 31 August 2026. Following this distribution, ACAPITAL Medi Holdco AS (under liquidation) no longer owns any shares in Medistim ASA.
…

Vis børsmeldingen

Upon the distribution of the liquidation proceeds, WQZ Investments Group Ltd received 1,815,978 shares in Medistim ASA and thereafter owns 1,815,978 shares in Medistim ASA, corresponding to 9.9% of the shares and votes in the company”

Peder Strand is a board member in Medistim ASA and primary insider in Medistim ASA. Attached is the PDMR notice sent to Finanstilsynet (Norwegian Financial Supervisory Authority)

Kilde

[TekBot]

Notice of extraordinary General Meeting in Medistim ASA

(Oslo, 14th of September 2026) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarters in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces the an extraordinary General Meeting for the company.

The extraordinary General Meeting will take place on the 5th of October 2026 at 10.00 and is held at Medistim’s offices at Økernveien 94 in Oslo. Attached are the agenda for the meeting and the voting form. Shareholders will receive a separate letter including reference and pin code to register votes. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further information on the use of proxy and voting,see general information at the bottom of the notice and enclosed proxy forms.
…

Vis børsmeldingen

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth over the past >15 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Canada, China, Germany, UK, Spain, Denmark, Sweden, Japan and Norway,in addition to the about 60 distributors in Europe, Asia, Middle East, Africa, Canada and South America.

For more information, visit the Medistim home page: www.Medistim.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act (Verdipapirhandelloven).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

Kilde

[Savepig]

Ikke så mange som snakker om Medistim, men finfin komponent i portisen i det siste

[TekBot]

Disclosure of voting rights in Medistim ASA

Øyvin Brøymer, Chairman of Medistim ASA, has received authorization for a total of 1,816,954 voting shares in connection with the extraordinary General Meeting in Medistim ASA the 5th of October 2026. This represents 9.91% of voting shares. Along with Brøymers shares through Fløtemarken AS and Intertrade Shipping AS that has 1,285,000 and 1,015,001 shares respectively, Brøymer votes for a total of 4,116,955 shares. This represents 22.45 % of the voting shares. The authorizations are valid for the extraordinary General Meeting in Medistim ASA the 5th of October 2026.
…

Vis børsmeldingen

Kilde

[TekBot]

Protocol from the extraordinary General Meeting in Medistim ASA

Attached is the protocol from the extraordinary General Meeting in Medistim ASA.
…

Vis børsmeldingen

Kilde

[Savepig]

God guff her i dag!

[TekBot]

Third quarter results and financials for 2026 for Medistim ASA

Medistim invites you to a presentation of the third quarter results and financials for 2026 and status for the company. The third quarter results and financials will be presented through a webinar. The webinar takes place Friday the 23rd of October 2026 and will start at 09.00 Norwegian time. The webinar will be available on Medistim website after the presentation.

Representatives for the company will be:
…

Vis børsmeldingen

Kari Eian Krogstad - CEO
Thomas Jakobsen - CFO

To sign up to join the
webinar please follow the link to register:
https://bit.ly/MedistimQ3Presentation2026

Kilde